Biotechnology Focus Podcast

The ups and down of an Ontario-based pharma company seeking to develop a solution for the world’s deadly opioid epidemic. A custom DNA nucleotide maker locks in on the problem of CRISP Cas9 off-targets I’m Nestor Arellano. And these are the biotech news we’ll talk about today on the Biotechnology Focus podcast +++ Intellipharmaceutics International of Etobicoke, Ont. was decidedly upbeat when it announced a couple of weeks ago the upcoming review by the FDA of its tamper resistant opioid medication called Rexista. Rexista was product squarely aimed at an unmet need. In recent years, Opioid addiction has become a major problem and growing cause of drug overdose deaths in Canada and the United States. At least 2,458 people were reported to have died in Canada last year due to opioid-related overdose. INtellipharma’s product appeared to promise to turn the tide. Rexista was being positioned as an abuse and alcohol-deterrent . It was a controlled-release oral formulation of oxycodone hydrochloride. A Bioequivalet